Shots:
- Bicycle receives $45M as up front and is eligible to receive development, regulatory and commercial milestones along with royalties for each program developed under the collaboration
- Ionis exercised its option for an exclusive license under the terms of a Dec’2020 evaluation and option agreement and get rights to evaluate tissue-targeting TfR1 binding Bicycles as vehicles to deliver oligonucleotide therapeutics and an option to obtain an exclusive license at the end of the evaluation period
- Bicycle retains the rights to use TfR1 Bicycles for all non-oligonucleotide therapies. Currently, Bicycle collaborates with DDF to advance potential TfR1 Bicycles for dementia
Click here to read full press release/ article | Ref: Business Wire | Image: Bicycle Therapeutics
The post Ionis Signs an Exclusive WW License Agreement with Bicycle to Develop Targeted Oligonucleotide Therapeutics Using TfR1 Bicycle Technology first appeared on PharmaShots.
